Serial Urinary Neopterin Measurements Reflect the Disease Course in Patients with Epithelial Ovarian Carcinoma Treated with Paclitaxel/Platinum Chemotherapy
Melichar Bohuslav,
Kalabova Hana,
Urbanek Lubor,
Malirova Eva,
Solichova Dagmar
Affiliations
Melichar Bohuslav
Klinika onkologie a radioterapie, Lekarska fakulta Univerzity Karlovy a Fakultni nemocnice, Budova 23, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. Tel +420-49-5834574; fax +420-49-583208
Kalabova Hana
Departments of Oncology & Radiotherapy, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic
Urbanek Lubor
Departments of Gerontology & Metabolic Care, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic
Malirova Eva
Departments of 4Nuclear Medicine, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic
Solichova Dagmar
Departments of Gerontology & Metabolic Care, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic
Increased concentrations of urinary neopterin, an indicator of systemic immune activation, have been reported in patients with cancer, including epithelial ovarian carcinoma (EOC). We have assessed urinary neopterin before the treatment and then daily during the therapy with paclitaxel/platinum combination in 5 EOC patients. A correlation was observed between the clinical course and serial urinary neopterin concentrations. We conclude that the determination of serial urinary neopterin concentrations may be useful for monitoring of EOC patients during chemotherapy.
